Oncozenge AB (ONCOZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncozenge AB (ONCOZ) has a cash flow conversion efficiency ratio of 12.336x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.24 Million ≈ $-779.25K USD) by net assets (Skr-587.00K ≈ $-63.17K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Oncozenge AB's balance sheet to measure how much of total assets are equity-financed.
Oncozenge AB - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Oncozenge AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ONCOZ operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Oncozenge AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncozenge AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Redivium Ltd
AU:RIL
|
2.594x |
|
Pan Entertainment Co. Ltd
KQ:068050
|
0.061x |
|
RLF Agtech Ltd
AU:RLF
|
-0.192x |
|
NEWMARK SECURITY LS-005
F:NN10
|
N/A |
|
Sadbhav Infrastructure Project Limited
NSE:SADBHIN
|
-0.797x |
|
Barramundi Group Ltd
OL:BARRA
|
0.044x |
|
CPL Group Public Company Limited
BK:CPL
|
-0.018x |
|
Leslies Inc
NASDAQ:LESL
|
0.166x |
Annual Cash Flow Conversion Efficiency for Oncozenge AB (2020–2025)
The table below shows the annual cash flow conversion efficiency of Oncozenge AB from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see ONCOZ stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-587.00K ≈ $-63.17K |
Skr-13.06 Million ≈ $-1.41 Million |
22.244x | +2625.38% |
| 2024-12-31 | Skr9.95 Million ≈ $1.07 Million |
Skr-8.76 Million ≈ $-943.15K |
-0.881x | +3.89% |
| 2023-12-31 | Skr18.64 Million ≈ $2.01 Million |
Skr-17.08 Million ≈ $-1.84 Million |
-0.916x | -41.02% |
| 2022-12-31 | Skr33.97 Million ≈ $3.66 Million |
Skr-22.08 Million ≈ $-2.38 Million |
-0.650x | -995.02% |
| 2021-12-31 | Skr80.32 Million ≈ $8.64 Million |
Skr-4.77 Million ≈ $-513.01K |
-0.059x | -173676.54% |
| 2020-12-31 | Skr29.28 Million ≈ $3.15 Million |
Skr-1.00K ≈ $-107.62 |
0.000x | -- |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.